1 reports of this reaction
4.5% of all LOBELIA INFLATA reports
#10 most reported adverse reaction
OCULAR HYPERAEMIA is the #10 most commonly reported adverse reaction for LOBELIA INFLATA, manufactured by Boiron. There are 1 FDA adverse event reports linking LOBELIA INFLATA to OCULAR HYPERAEMIA. This represents approximately 4.5% of all 22 adverse event reports for this drug.
Patients taking LOBELIA INFLATA who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is moderately reported among LOBELIA INFLATA users, representing a notable but not dominant share of adverse events.
In addition to ocular hyperaemia, the following adverse reactions have been reported for LOBELIA INFLATA:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 1 FDA reports for LOBELIA INFLATA. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 4.5% of all adverse event reports for LOBELIA INFLATA, making it a notable side effect.
If you experience ocular hyperaemia while taking LOBELIA INFLATA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.